NCT06544629|Recruiting
Imjudo & Imfinzi PMS
Imjudo & Imfinzi Post-Marketing Surveillance
Loading search results
Imjudo & Imfinzi Post-Marketing Surveillance
Sponsor study identifier
observational
246
1 country
6
Study Start
April 14, 2025
Actual (reported)Primary Completion
December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 6, 2024
Actual (reported)August 9, 2024
Actual (reported)April 14, 2025
Actual (reported)December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs)
To assess safety of the study drugs for patients treated with the study drugs under the approved indication in Korea
For Imjudo will be conducted for 90 days from the first dose of the treatment. For Imfinzi will be separately conducted for 1 year from the first dose.
Objective Response Rate(ORR)
For 1 year from the first dose of the treatment
Disease Control Rate (DCR)
For 1 year from the first dose of the treatment
Patients who initiate treatment with study drugs after the contract date for the first time.
Research Site
Busan, South Korea
Research Site
Goyang, South Korea
Research Site
Seongnam, South Korea
Research Site
Seoul, South Korea
AstraZeneca Clinical Study Information Center
CONTACT
First Submitted
August 6, 2024
First Posted
August 9, 2024
Study Start
April 14, 2025
Actual (reported)Primary Completion
December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Research Site
Seoul, South Korea
Research Site
Suwon, South Korea
Study Completion
December 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 5, 2026
Record last verified: 2026-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: